Podcasts about Hesham

In this episode of Ara Ara The Weeb Podcast, we sit down with Hesham Elshazly, an English voice actor whose journey spans Egypt, the United States, and now Dubai.We talk about how growing up between cultures shaped his voice acting career, how he broke into the industry, how voicing video games differs from anime, and what it's really like working on English voice acting projects. Hesham shares insights on voicing video games like New World and Metal Slug Awakening, animes such as The Journey and Nukitashi, as well as his experience training under the top voice acting coaches in the world. If you're curious about anime dubbing and voice acting careers this episode is for you!

In this episode, Dr. Hesham A. Hassaballa, Medical Director of Critical Care and Respiratory Therapy at Rush-Copley Medical Center, discusses how AI is transforming clinical care, the irreplaceable human elements of medicine, and the leadership values that guide his work. He also shares insights on physician excellence, system-level improvement, and what inspires him as he looks ahead to 2026.

In this episode, Dominic Bowen and Hesham Youssef discuss the growing tensions between Egypt and Israel, the fragile state of regional diplomacy, and the pressures placed on long-standing agreements such as the Camp David Accords. Find out more about why Egypt views forced displacement from Gaza as an existential red line, how humanitarian access has become a major point of contention, and the shifting political dynamics inside Israel that are influencing regional instability. The conversation also addresses the role of the United States and Europe in shaping (or failing to shape) constructive pathways toward peace, as well as Egypt's mediation efforts across repeated Gaza conflicts. Finally, they explore the broader humanitarian crisis in Gaza, the future of Palestinian governance, and the personal diplomatic experiences that have shaped Ambassador Youssef's understanding of what is still possible in the Middle East.Hesham Youssef is an Egyptian career diplomat and conflict-resolution expert with over three decades of experience in Middle Eastern diplomacy. He has served in senior roles at the Arab League, the Organization of Islamic Cooperation (OIC), and as a Senior Fellow at the United States Institute of Peace. Currently a Senior Advisor at the European Institute of Peace, Youssef specializes in humanitarian affairs, Arab-Israeli relations, and institutional reform in the Arab world. His career reflects a lifelong commitment to dialogue, peacebuilding, and multilateral diplomacy across the Islamic world.The International Risk Podcast brings you conversations with global experts, frontline practitioners, and senior decision-makers who are shaping how we understand and respond to international risk. From geopolitical volatility and organised crime to cybersecurity threats and hybrid warfare, each episode explores the forces transforming our world and what smart leaders must do to navigate them. Whether you're a board member, policymaker, or risk professional, The International Risk Podcast delivers actionable insights, sharp analysis, and real-world stories that matter.Dominic Bowen is the host of The International Risk Podcast and Europe's leading expert on international risk and crisis management. As Head of Strategic Advisory and Partner at one of Europe's leading risk management consulting firms, Dominic advises CEOs, boards, and senior executives across the continent on how to prepare for uncertainty and act with intent. He has spent decades working in war zones, advising multinational companies, and supporting Europe's business leaders. Dominic is the go-to business advisor for leaders navigating risk, crisis, and strategy; trusted for his clarity, calmness under pressure, and ability to turn volatility into competitive advantage. Dominic equips today's business leaders with the insight and confidence to lead through disruption and deliver sustained strategic advantage.The International Risk Podcast – Reducing risk by increasing knowledge. Follow us on LinkedIn and Subscribe for all our updates!Tell us what you liked!Tell us what you liked!

Recently, I spoke with Hesham Nazih, who is the composer for the new Marvel Disney+ Original series, "Eyes Of Wakanda", where I asked him about the differences in moving from creating music for live-action shows like "Moon Knight", to animated shows and much more.   "Eyes of Wakanda" is out now on Disney+, and the soundtrack is available on all major digital platforms.

Recently, I spoke with Hesham Nazih, who is the composer for the new Marvel Disney+ Original series, "Eyes Of Wakanda", where I asked him about the differences in moving from creating music for live-action shows like "Moon Knight", to animated shows and much more.   "Eyes of Wakanda" is out now on Disney+, and the soundtrack is available on all major digital platforms.

Recently, I spoke with Hesham Nazih, who is the composer for the new Marvel Disney+ Original series, "Eyes Of Wakanda", where I asked him about the differences in moving from creating music for live-action shows like "Moon Knight", to animated shows and much more.   "Eyes of Wakanda" is out now on Disney+, and the soundtrack is available on all major digital platforms.

Are you looking for innovative ways to boost your nonprofit's revenue and expand your reach? In this episode, we explore the often-overlooked strategy of affiliate marketing and how it can benefit mission-driven organizations. I sit down with Aya Hesham, CEO of Vivian Agency, to uncover the potential of strategic partnerships that align with your cause and resonate with your audience. Demystifying Affiliate Marketing for Nonprofits Aya breaks down the concept of affiliate marketing and explains why it's a powerful tool for nonprofits: - Creating mutually beneficial partnerships with aligned businesses - Generating additional revenue streams without compromising your mission - Offering supporters new ways to contribute to your cause Finding the Right Partners Discover practical strategies for identifying and approaching potential affiliate partners: - Analyzing your audience to determine relevant products and services - Leveraging affiliate networks to streamline the process - Ensuring partners align with your organization's values and mission Implementing Affiliate Marketing with Authenticity Learn how to integrate affiliate partnerships into your nonprofit's communication strategy: - Crafting genuine stories around recommended products - Balancing promotional content with your core messaging - Testing and refining your approach to maximize engagement Overcoming Common Concerns We address potential hesitations about affiliate marketing in the nonprofit sector: - Maintaining ethical standards and transparency - Focusing on value-add for your audience rather than “pushing” products - Viewing partnerships as an extension of your mission, not just a revenue source Whether you're a small grassroots organization or an established nonprofit, this conversation offers fresh insights on diversifying your income streams while providing additional value to your supporters. Don't miss this opportunity to explore a strategy that could transform your approach to partnerships and sustainability. Want to skip ahead? Here are some key takeaways: 05:23 Identifying Relevant Affiliate Opportunities Learn how to research and select partners that align with your cause and resonate with your audience. 12:47 Crafting Authentic Promotional Content Discover strategies for sharing affiliate offers in a way that feels genuine and adds value to your community. 19:36 Integrating Affiliate Marketing into Your Strategy Explore practical tips for incorporating affiliate partnerships into your existing communication channels and content plan. 26:15 Scaling Your Affiliate Program Understand the time investment required and how to grow your affiliate marketing efforts sustainably. Aya Hesham Turning Partnerships into profit, Aya helps brands scale their revenue and visibility through strategic Affiliate & Influencer partnerships. As the CEO of Vivian Agency, she leads a team of top specialists dedicated to building communities for brands by connecting ambassadors and their audiences to the products they love. Learn more at VivianAgency.com https://www.linkedin.com/company/vivianagency/ https://www.linkedin.com/in/aya-elrahman-saad-799638213/ Connect with us on LinkedIn: https://www.linkedin.com/company/the-first-click Learn more about The First Click: https://thefirstclick.net Schedule a Digital Marketing Therapy Session: https://thefirstclick.net/officehours

Welcome to the eCommerce Lab Podcast! Join us as we explore the world of e-commerce with Abdallah Hesham, a 6-figure Amazon seller and expert content creator. Discover with us the most effective strategies for finding and selecting the best products to sell on Amazon. Get ready to learn how to identify lucrative opportunities and optimize your success on the world's largest marketplace!Don't forget to subscribe so you don't miss this valuable episode!

What happens when technology levels the playing field—when education, innovation, and opportunity become more accessible than ever before? For many, AI is that transformative force, acting as the Great Equalizer across industries. Live from MWC Barcelona, host Matthew Roberts is joined by Tomer Gingold from Amdocs and Hesham Fahmy, Chief Information Officer at TELUS, to explore AI's ever-evolving impact. Hesham kicks things off by breaking down TELUS's transformation from a traditional telecom company to a tech-driven powerhouse, shifting IT from a cost center to a strategic value creator. He also highlights AI's power in education and knowledge democratization, making information more accessible while revolutionizing the way businesses operate. The discussion delves into AI's societal impact and its alignment with TELUS's mission to use technology for social good. Looking ahead, the trio examines AI's rapid adoption, shifting public perceptions, and what the next 12 months might hold. Discover how AI isn't just driving innovation—it's making knowledge more accessible than ever.

What if your biggest business breakthrough came from a completely different industry? In this episode, Dr. Hesham Baky shares how he transitioned from scaling a multi-location dental empire to building a $230M real estate portfolio focused on high-growth medical retail spaces what he calls "Medtail." Discover the game-changing strategy he used to identify prime locations before they boom, leverage real estate for massive returns, and create a fund that attracts both medical professionals and high-net-worth investors. 5 Key Takeaways from the Episode with Dr. Hesham BakyThe Power of Owning the Real Estate Behind Your Business Dr. Baky learned from a mentor that owning the real estate where your business operates provides long-term financial stability. This insight led him to acquire properties alongside his dental practices, ultimately fueling his expansion into commercial real estate.Medtail: The Future of Medical Real Estate Investment The shift of medical services into retail spaces—dubbed "Medtail"—is a high-growth trend. By placing medical offices in high-traffic retail locations, Dr. Baky has been able to create more patient-friendly experiences while capitalizing on the value of mixed-use developments.Using Heat Mapping to Predict Real Estate Growth Instead of relying solely on census data, Dr. Baky and his team developed a proprietary heat-mapping system based on future housing permits. This allowed them to identify high-growth areas before they developed, securing prime real estate at a fraction of its future value.The Benefits of a Fund Structure for Scaling Investments While initially focused on personal real estate investments, Dr. Baky realized the power of pooling investor capital. His Blue Ridge Capital Fund allows doctors and high-net-worth individuals to participate in lucrative real estate opportunities while benefiting from his expertise.Trend-Based Investing vs. Asset-Based Investing Dr. Baky's success stems from spotting emerging trends rather than being tied to a single asset class. From identifying Medtail as a rising investment opportunity to capitalizing on distressed retail centers during COVID, his ability to recognize market shifts has led to significant wealth creation.About Tim MaiTim Mai is a real estate investor, fund manager, mentor, and founder of HERO Mastermind for REI coaches.He has helped many real estate investors and coaches become millionaires. Tim continues to help busy professionals earn income and build wealth through passive investing.He is also a creative marketer and promoter with incredible knowledge and experience, which he freely shares. He has lifted himself from the aftermath of war, achieving technical expertise in computers, followed by investment success in real estate, management skills, and a lofty position among real estate educators and internet marketers.Tim is an industry leader who has acquired and exited well over $50 million worth of real estate and is currently an investor in over 2700 units of multifamily apartments.Connect with TimWebsite: Capital Raising PartyFacebook: Tim Mai | Capital Raising Nation Instagram: @timmaicomTwitter: @timmaiLinkedIn: Tim MaiYouTube: Tim Mai

Pr. Hesham Shehab of Peace Lutheran-Lombard, IL and Salam Christian Fellowship   The post The Islamic Holy Month of Ramadan – Pr. Hesham Shehab, 2/28/25 (0594, Encore) first appeared on Issues, Etc..

Josh Sebo (COO of OfferVault), Adam Young (CEO of Ringba), industry legend Harrison Gevirtz and special guest Aya Hesham (Director of Partnerships at Vivian Agency) discuss: - Vivian Agency: Why is it "women-only?" - How to launch and manage affiliate programs for your business - Do's & Don'ts of Affiliate Marketing - How to grow your business with affiliates - When is the right time to launch an affiliate program? Follow Us: OfferVault: WEBSITE: https://www.offervault.com/ FACEBOOK: https://www.facebook.com/offervault INSTAGRAM: https://www.instagram.com/offervaultmarketing/ TWITTER: https://www.twitter.com/offervault LINKEDIN: https://www.linkedin.com/company/offer-vault/ Adam Young: RINGBA: https://www.ringba.com RINGBA's INNER CIRCLE: https://try.ringba.com/inner-circle/ FACEBOOK: https://www.facebook.com/ringba INSTAGRAM: https://www.instagram.com/adamyoung/ TWITTER: https://www.twitter.com/arbitrage LINKEDIN: https://www.linkedin.com/in/capitalist Harrison Gevirtz: INSTAGRAM: https://www.instagram.com/affiliate/ LINKEDIN: https://www.linkedin.com/in/harrisongevirtz/ Aya Hesham: VIVIAN AGENCY: https://www.vivianagency.com/ LINKEDIN: https://www.linkedin.com/in/aya-elrahman-saad-799638213/

Dave travels to Cairo, Egypt, for a fascinating interview with Dr. Hesham Sallam, Egypt's leading paleontologist and founder of the country's first Vertebrate Paleontology Center. As a fellow Paleo Nerd, Dr. Sallam shares insights into his groundbreaking work, his efforts to bring more women into the field, and the thrilling discoveries shaping Egypt's prehistoric story.

In this episode of the CanadianSME Small Business Podcast, we are joined by Hesham Fahmy, Chief Information Officer at TELUS. Hesham has been instrumental in guiding TELUS through a significant digital transformation, incorporating advanced technologies like AI and cloud solutions to enhance operational efficiency and customer service. He shares insights into TELUS' journey, the impact of AI on customer support, and the ethical considerations of AI deployment.Key Highlights:Hesham describes TELUS' transition from a traditional telecom to a digital-first, software-centric organization.Discussion on TELUS' development of a GenAI-powered customer support tool.Exploration of how TELUS addresses ethical considerations and data privacy in its AI applications.Hesham offers advice to other business leaders on adopting AI technologies effectively within their operations.Hesham shares exciting future projects and initiatives that continue to position TELUS as a leader in technology and customer service.We thank Hesham Fahmy for his enlightening conversation and for sharing his expertise in driving one of Canada's leading tech transformations. His insights are essential for anyone in the tech sector or any business leader looking to embrace digital and AI advancements.Shoutout to our sponsors for more information find their links below:RBC: https://www.rbcroyalbank.com/dms/business/accounts/beyond-banking/index.htmlUPS: https://solutions.ups.com/ca-beunstoppable.html?WT.mc_id=BUSMEWAXero: https://www.xero.com/ca/?source=CanadianSMEConstant Contact:  https://www.constantcontact.com/landing1/new-marketer?utm_campaign=canadiansme&utm_medium=sponsorlogo&utm_source=brand   IHG Hotels and Resorts: https://businessedge.ihg.com/s/?language=en_USDon't forget to subscribe to CanadianSME Small Business Magazine at www.canadiansme.ca  for more insightful episodes that empower your entrepreneurial spirit.

On this episode of Pophealth Week, we feature Hesham Hessaballa MD, a pulumonary and critical care medicine specialist practicing for more than 20 years. Dr. Hassaballa is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine, serves as Assistant Professor Rush University & Medical Center, and Editor of the popular blog @MedikaLife keep up with Dr. Hassaballa's work on Twitter profile @HAHassaballaMD or on linkedIn, or on the web via www.drhassaballa.com. We discuss his journey into critical care medicine and explore his '11 rules for the ICU' recommendations outlined in 'How Not to Kill Someone in the ICU'. Follow Dr. Hassaballa's work on Twitter via @HAHassaballaMD, on linkedIn, or on the web via www.drhassaballa.com.

On this episode of Pophealth Week, we feature Hesham Hessaballa MD, a pulumonary and critical care medicine specialist practicing for more than 20 years. Dr. Hassaballa is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine, serves as Assistant Professor Rush University & Medical Center, and Editor of the popular blog @MedikaLife keep up with Dr. Hassaballa's work on Twitter profile @HAHassaballaMD or on linkedIn, or on the web via www.drhassaballa.com. We discuss his journey into critical care medicine and explore his '11 rules for the ICU' recommendations outlined in 'How Not to Kill Someone in the ICU'. Follow Dr. Hassaballa's work on Twitter via @HAHassaballaMD, on linkedIn, or on the web via www.drhassaballa.com.

Hosts Fred Goldstein and Gregg Masters MPH talk to Hesham Hessaballa MD, a pulumonary and critical care medicine specialist practicing for more than 20 years. Dr. Hassaballa is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine, serves as Assistant Professor Rush University & Medical Center, and Editor of the popular blog @MedikaLife. They discuss his journey into critical care medicine and explore his '11 rules for the ICU' recommendations outlined in 'How Not to Kill Someone in the ICU'. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Best Movies - Top 10  Top Movies  Salaar - very good commercial movie after a long gap Miss Shetty Mr Polishetty - except first 25 mins, Naveen Polishetty comic timing and screen presence carried entire movie and made it funny  Hi Nanna - With pure emotion director tug your heartstrings along with amazing acting and awesome BGM and songs from Hesham. Shouryuv director to watch out for 35 crores share  Samajavaragamana - my favorite type of movie, switch of son helping his father getting a degree was hilarious along with rakhi scenes and whole Vennela Kishore track. Except last 15 mins, hilarious movie Need more movies like this. Clean family entertainers.  MAD - hilarious movie with funny one liners. Friendship, beautiful girls, catchy songs, what else do you want from a youth movie. Sangeeth Sobhan next big talent in Telugu cinema.  Bhagavanth Kesari - unexpected movie from Ravipudi and Balayya, 0 cringe with a good message about women empowerment along with presentation of Balayya and elevations and commercial elements, it was a refreshing movie to see Balayya play his age and design mass within that.   Balagam - comedy was great but lot of melodrama. However it showed culture in a great light  Writer Padmabushan - idgaf what anyone says, movie was great and I laughed a lot. Clean movie  Virupaksha - I didnt like it it was so weird but the sound design, cinematography, direction, BGM, and production design were all outstanding. A genre movie 100 crores range ante its huge.  Bedurulanka - interesting and funny movie about exploitation of society with village heads conning people  Worst 5  Skanda - rod, so much athi,  Veera Simha Reddy - worst writing and worst fights and worst story and flashback, such a fucking boring movie  Dasara - boring fucking movie except climax  Baby - Anand is a pussy, Vaishnavi is a bigger pussy, and Viraj is the biggest pussy  Adipurush - Watch Chota Bheem or Hanuman with Chiranjeevi, it's way better  Special mention: Waltair Veerayya not Chiru range movie and acting was very artificial very overrated movie bad album and then Boss saying hey have 2.25 ratings but we did 2.25 million,   Rangabali, Kushi, Tiger Nageswara Rao, Bro, Mem Famous, Anni Manchi Sakunamule - Nanindi Reddy said my film will have a self life of 25 years despite the bad talk. Nobody will watch it again.  Top 10 Songs: Needhe Needhe - from Hi Nanna  Samayama - Hi Nanna  Ye Vaipukuki Saguthondi from Miss Shetty  Dum Masala from Guntur Kaaram Lady Luck from Guntur Kaaram  Swaasa Meeda Dyaasa - Keeda Cola  Ram Sita Ram from Adipurush  Priya Mithunam from Adipurush  Aradhya from Kushi  Adigaa from Hi Nanna  Worst Songs of the year: Poonakallu Loading from Waltair Veerayya, Cult Mama from Skanda, Ole Ole Pappayi from Extra Ordinary Man  Awards  Hero of the year: Prabhas two highest grossing movies but result wise Adipurush disaster and then Salaar TBA  Best film - Salaar  Best Director: Prashanth Neel for Salaar  Special mention: Ram Abbaraju for Samajavaragamana  Best Actor - Naveen Polishetty for MSMP  Special Mention: Nani for Dasara  Best Actress: Mrunal Thakur  Special Memtion - Samyuktha Menon for Virupaksha  Best Debut Male - Sangeeth Sobhan for MAD  Best Debut Actress - Vaishnavi Chaitanya for Baby  Song of the Year - Needhe Needhe from Hi Nanna  Singer of the year male - Karthik (Nachavule, Adipurush 2 songs, Anni Manchi Sakunumule title song, Adigaa Hi Nanna)  Singer of the year female - N/A  Best Supporting Actor: Naresh for Samajavaragamana, Raviteja for Waltair Veerayya  Best Supporting Actress: Rohini for Writer Padmabushan  Best Cinematography: Sathyan Sooryan for Dasara, Bhuvan Gowda for Salaar  Worst movie: Bhola Shankar, Agent and Veera Simha Reddy Worst Director: Meher Ramesh, Surender Reddy and Gopichand Malineli  2024 Preview  Guntur Kaaram  Saindhav  Devara  Pushpa 2  Kalki 2898  Game Changer  OG  Ustaad Bhagat Singh  Hari Hara Veera Mallu  Saripodha Sanivaaram  VD12 

Impression: All-Ohio First Team Urologist Dr. Hesham Mostafa describes to Saad and Travis his journey growing up in Cleveland to parents of Egyptian descent, attending The Ohio State University, graduating from the University of Cincinnati College of Medicine and completing Urology residency at the University of Toledo Medical Center specializing in robotic and minimally invasive surgery before practicing in Northwest Ohio.

Payman chats with Hasham Ali about his journey from the Middle East to Manchester, UK, where he now practices as a specialist orthodontist.    Hesham discusses the value and challenges of professional networking, what it takes to turn GDPs into competent orthodontists, and why the term specialist orthodontist will always be a secondary identity.     In This Episode 02:00 - Specialising 08.04 - The UK, NHS and private work 12.15 - Networking, communication and social media 24.57 - Teaching and events 28.28 - Roots and relationships 37.15 - Ortho training, planning and treatment 57.35 - Blackbox thinking 01.02.54 - Knowing Vs not knowing 01.06.05 - Orthodontics and health 01.11.06 - Dark days 01.21.21 - In retrospect 01.22.55 - Free time 01.25.24 - Being a twin 01.27.58 - Fantasy dinner party 01.35.49 - Last days and legacy About Hesham Ali Hesham Ali is a specialist orthodontist and consultant at the Royal Bolton Hospital in Greater Manchester. He also teaches orthodontics through his Orthodontia brand.  

هاني مدبولي شريك و مدير شركة أوف رود إيجيبت المتخصصة في تعديل سيارات الدفع الرباعي و الملاح في فريق رحالة للسباقات يت. و هشام فاروق  مدير التصوير السينمائي و عاشق للصحراء و احد روادهاProduced by: Abbas Aboelhassan Chapters00:00 Intro00:27 فريق رحالة06:03 الف كيلو على الحصان13:42 رالي الفراعنة21:15 موسم الصحراء37:54 الخبرة هي الأساس58:50 الدعم والسياحةFollow: rwa.podcast.egInstagram: https://www.instagram.com/rwa.podcast.eg/Facebook: https://web.facebook.com/rwa.podcast.egTwitter: https://twitter.com/rwa_podcast_egTiktok: https://www.tiktok.com/@rwa.podcast.egFollow Abbas Aboelhassan: Instagram: https://www.instagram.com/abbasaboelhassanofficial/Facebook: https://web.facebook.com/AbbasyzListen to our podcast: https://www.buzzsprout.com/1248233#rwapodcast #abbasaboelhassan #podcast #rantswithabbas

Host Gil Bashe chats with Rush based and board Certified in Internal Medicine, Pulmonary Medicine, Critical Care Medicine, and Sleep Medicine, Dr. Hesham A. Hassaballa, a Fellow of the American College of Physicians and author of "How Not To Kill Someone In The ICU: A Practical Guide For A Successful Rotation, Or Career, In The Intensive Care Unit." Dr. Hassaballa has a strong interest in the integration of spirituality and medicine, and he has written extensively on this topic. He is the author of several books, including ""The Believer's Guide to Ramadan"" and ""The Beliefnet Guide to Islam."" His writings have been featured in various publications, including the Huffington Post, Chicago Tribune, and the Washington Post. Book Link: https://www.amazon.com/How-Not-Kill-Someone-ICU/dp/0985326514 To keep tabs on Dr. Hassaballa follow on twitter via @HAHassaballaMD or on the web at www.drhassaballa.com To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

We've all heard of the Arab League, but we wanted to know more about its history, intended purpose and its inner workings. Ambassador Hesham Youssef joined us for a fascinating conversation about foreign-affairs, Arab geopolitics, and to help us better understand this key regional institution.In this episode, we cover the history of the Arab League, its activities and impact, and what Ambassador Youssef predicts for the future of our region.Ambassador Hesham Youssef was a career diplomat, posted to Canada and the Egyptian Mission in Geneva during his time at the Egyptian Foreign Ministry. He went on to work at the Arab League and now works at the Organisation of Islamic Cooperation.He has extensive experience working in conflict resolution in the Middle East, with particular focus on the Arab-Israeli conflict, reconciliation in Iraq and the situation in Sudan. He has also worked on economic and trade issues with the UN and the WTO.Created & Hosted by Mikey Muhanna, afikraEdited by: Ramzi RammanTheme music by: Tarek Yamani https://www.instagram.com/tarek_yamani/About the afikra Conversations:Our long-form interview series features academics, arts, ‎and media experts who are helping document and/or shape the history and culture of the Arab world through their ‎work. Our hope is that by having the guest share their expertise and story, the community still walks away with newfound curiosity - and maybe some good recommendations about new nerdy rabbit holes to dive into headfirst. ‎FollowYoutube - Instagram (@afikra_) - Facebook -Twitter Support www.afikra.com/supportAbout afikra:‎afikra is a movement to convert passive interest in the Arab world to active intellectual curiosity. We aim to collectively reframe the dominant narrative of the region by exploring the histories and cultures of the region- past, present, and future - through conversations driven by curiosity. Read more about us on  afikra.com  

لقاء مع الفنان القدير هشام عبد الله من المنفى فى تركيا. لماذا شارك فى الثورة وكيف ترك مصر وماذا حدث عندما اختطفته المخابرات الحربية 6 ساعات اثناء الثورة.

We know the ‘system' has challenges and in many ways is responsible for the way we work with or against each other, knowingly or unknowingly. Can quality improvement approaches help sustain our reasons for being in healthcare? FURTHER LEARNING If you're a member of Medical Protection and want to learn more: Understanding human factors to improve clinical performance and patient safety [Recorded Webinar] https://protection.pub/3CE4y7z Introduction to Human Factors [eLearning] https://protection.pub/3Nj6SWx For more information about the Patient Safety Incident Response Framework & Hexitime https://www.england.nhs.uk/patient-safety/incident-response-framework/ https://vimeo.com/617883668 https://www.youtube.com/watch?v=9FL1E6KZ4Ak CERTIFICATE A certificate of learning for listening is available on PRISM https://protection.pub/3WtX54j SPEAKERS Our host today was Dr Najeeb Rahman Our guest speaker today was Dr Hesham Abdalla For more information about Medical Protection please visit www.medicalprotection.org

Please join Guest Host Maryjane Farr, authors Sarah Franklin and Stavros G. Drakos, as well as Associate Editor Hesham Sadek as they discuss the article "Distinct Transcriptomic and Proteomic Profile Specifies Heart Failure Patients With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your cohosts. I'm Dr. Carolyn Lam, associate editor from the National Heart Center in Duke National University of Singapore. Dr. Peder Myhre: And I'm Dr. Peder Myhre, social media editor from Akershus University Hospital and University of Oslo. Dr. Carolyn Lam: Peder, today's featured paper is very, very important in the heart failure world. It is such a deep dive into the transcriptomic and proteomic profile that specifies heart failure and the potential of myocardial recovery with mechanical unloading and circulatory support. Dr. Peder Myhre: Can't wait for that feature discussion today, Carolyn. Dr. Carolyn Lam: But you have to wait because I insist on telling you about yet another really important paper, of course in my favorite subject, heart failure with preserved ejection fraction or HFpEF. Now you know that exercise intolerance is a defining characteristic of HFpEF and a marked rise in pulmonary capillary wedge pressure during exertion is pethepneumonic for HFpEF and it's thought to be a key cause of the exercise intolerance. Now if that is true, acutely lowering the wedge pressure should improve exercise capacity, right? Well, don't assume this because to test this hypothesis, authors led by corresponding author Dr. Ben Levine from UT Southwestern evaluated peak exercise capacity with and without nitroglycerin, which was used to acutely lower pulmonary capillary wedge pressure during exercise in patients with HFpEF. Dr. Peder Myhre: Oh, that's so cool. What an amazing research question and Carolyn, you're the best to summarize this. Please tell us what did they find? Dr. Carolyn Lam: Well, they studied 30 patients with HFpEF and get this. They underwent two bouts of upright seated cycle exercise dosed with sublingual nitroglycerin or a placebo every 15 minutes in a single blind randomized crossover design. So really well done. Wedge pressure, VO2 and cardiac output were assessed at rest with 20 watts exercise and at peak exercise during both the placebo and nitroglycerin conditions and the principle finding of the study (singing) acutely lowering pulmonary capillary wedge pressure during upright exercise with nitroglycerin in HFpEF did not improve peak exercise performance. So peak VO2 was practically identical with a 1% difference despite a 17% drop in peak wedge pressure. Peak cardiac output and peak peripheral oxygen extraction were unchanged, again, despite the drop in peak wedge pressure suggesting that oxygen delivery and utilization were unaffected. Exercise performance variables including peak wattage, peak ventilation and peak RER were unchanged, suggesting that again, reductions in peak wedge were insufficient to improve exercise tolerance. All these results suggest acute reductions in wedge pressure are insufficient to improve exercise capacity and provide convincing evidence that a high wedge during exercise by itself is an epiphenomenon perhaps rather than a primary limiting factor for exercise performance in patients with HFpEF. Now of course this is incredibly interesting contrary to hypothesis and so please read the paper. The discussion is very rich. Dr. Peder Myhre: Oh wow, Carolyn. That is such a great paper. I can't wait to pick it up and read it from start to finish and now Carolyn, we're going to look into research within cardiovascular disease from COVID-19 and we have learned so much and so quickly about COVID-19 and its effects on the heart and we have really come a long way from the first case reports reported in the beginning of the pandemic and this paper, which comes to us from corresponding author Professor JP Greenwood, really adds important knowledge to this field. The COVID heart study was a prospective longitudinal multi-center observational cohort study of patients hospitalized with COVID-19 and at elevated serum troponin levels across 25 hospitals in the UK and these investigators aim to characterize myocardial injury, its association and sequela in convalescent patients following hospitalization with COVID-19 utilizing appropriately matched contemporary controls. Dr. Carolyn Lam: Ooh, important stuff. So what did they find? Dr. Peder Myhre: So these authors included in total 519 patients comprising 342 patients with COVID-19 and an elevated troponin, 64 patients with COVID-19 and a normal troponin and 113 age and comorbidity matched controls without COVID-19 and the frequency of any heart abnormality defined as left or right ventricular impairment, scar or pericardial disease was two full greater in patients with COVID positive and troponin positive, so 61% compared to the control groups and that is 36% for COVID positive and troponin negative and 31% for COVID negative and comorbidity positive and the myocardial injury pattern was different for these patients with COVID and an elevated troponin more likely than controls to have infarction and micro infarction. But there was no difference in non-ischemic scar and using the late MRI criteria, the prevalence of probable recent myocarditis was almost 7% for those with COVID and elevated troponin compared to only 2% for the controls without COVID-19 and myocardial scar is but not prior COVID-19 infection or troponin was an independent predictor of MACE. So Carolyn, these authors discussed their findings in light of previously reported studies and these authors identified a lower prevalence of probable recent myocarditis than previously described and a higher proportion of myocardial infarction and this newly described pattern of micro infarction following COVID-19 and Carolyn, there is a brilliant editorial really summarizing this by Dr. Stuber and Baggish entitled "Acute Myocardial Injury in the COVID Heart Study Emphasizing Scars While Reassuring Scarce." I really recommend everyone to pick this up and read the editorial as well. Dr. Carolyn Lam: Very clever title. Thank you. For the last original paper in today's issue, it focuses on the crosstalk between sterile metabolism and inflammatory pathways, which have been demonstrated to significantly impact the development of atherosclerosis. Authors today are featuring and focusing on 25 hydroxy cholesterol, which is produced as an oxidation product of cholesterol and belongs to a family of bioactive cholesterol derivatives produced by cells in response to fluctuating cholesterol levels and immune activation. So these authors with co-corresponding authors, Dr. Suárez and Fernández-Hernando from Yale University School of Medicine, they showed beautifully that first, 25 hydroxy cholesterol accumulates in human coronary atherosclerosis. Next, that 25 hydroxy cholesterol produced by macrophages accelerated atherosclerosis progression and promoted plaque instability by promoting the inflammatory response in macrophages and also via paracrine actions on smooth muscle cell migratory responses. Dr. Peder Myhre: Wow, that is so interesting, Carolyn. What are the therapeutic implications of these findings? Dr. Carolyn Lam: Yes, I'm glad you asked because it was summarizing a lot of work in those findings with the very important implications that inhibition of 25 hydroxy cholesterol production might therefore delay atherosclerosis progression and promote plaque stability. So this study actually opens a door to explore the role of 25 hydroxy cholesterol as a target to control inflammation and plaque stability in human atherosclerosis. Dr. Peder Myhre: Oh, that is so important. Thank you so much and there is more in this issue as well, Carolyn. We have another issue of Circulation Global Rounds and this time we're going to France in a paper written by Dr. Danchin and Bouleti. We also have an exchange of letters by Dr. Yang and Dr. Schultze regarding the article, "Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation" and an ECG Challenge by Drs. Manickavasagam, Dar and Jacob entitled "Syncope After Transcatheter Aortic Valve Implantation: Pace or Not." Dr. Carolyn Lam: Interesting. There's a Frontiers paper also by Dr. Dimopoulos on “Cardiovascular Complications of Down Syndrome: Scoping Review and Expert Consensus,” a Research Letter by Dr. Kimenai on the impact of patient selection on performance of an early rule out pathway for myocardial infarction from research to the real world. Nice. Well let's carry on to that feature discussion on heart failure, transcriptomics and proteomic, shall we? Dr. Peder Myhre: Can't wait. Dr. Maryjane Farr: Welcome everybody to Circulation on the Run. We are so pleased to be talking with Dr. Stavros Drakos and Dr. Sarah Franklin from the University of Utah. My name is Maryjane Farr and I am the heart failure section chief at UT Southwestern and Digital Strategies editor for circulation. Myself and Hesham Sadek will be talking with them about their new paper and circulation called "Distinct Transcriptomic and Proteomic Profile Specifies Heart Failure Patients with Potential of Myocardial Recovery Upon Mechanical Unloading and Circulatory Support." Just briefly, Dr. Stavros Drakos is the director of cardiovascular research for the division of cardiology at Utah and co-director of the Heart Failure Mechanical Circulatory Support and Heart Transplant Program. Dr. Sarah Franklin is associate professor of medicine at the University of Utah whose lab has a specific expertise in the applications of proteomics to heart disease. Welcome, Stavros and Sarah. Dr. Sarah Franklin: Thank you. Dr. Stavros Drakos: Thank you. Thank you for having us. Dr. Maryjane Farr: This paper is exciting for clinicians. It's exciting for translational scientists. Hesham, why don't you start digging into this paper and tell us one or then the other of you tell us what this paper is about, what's the background and let's get into the science. Let's go there and then we'll pull back and look at some of the big picture stuff. Hesham. Hesham Sadek: Well, thank you. So I've been fascinated by the field of cardiac recovery for some time now and obviously Stavros is as an expert and one of the leaders of that field and what struck me about this is that we are starting to see some distinct molecular signature of patients that can experience recovery as opposed to patients undergoing the same procedures with the same profile that do not manifest evidence of myocardial recovery and specifically, the study was conducted very rigorously and the signature was very clear in that they saw primarily interest for someone like me who's interested in cardiac regeneration, a signature of cell cycle in the patients that experience recovery as well as ECM signature which could suggest reverse remodeling and also there's some evidence that ECM might impact cardiomyocyte and myocardial regeneration. So my interest in this for selfish reasons is primarily that this supports the hypothesis that perhaps there is a molecular signature of regeneration that occurs in patients that experience myocardial recovery with LVAD. Dr. Maryjane Farr: So Stavros, let's start with you. Give us the reason why to do this study. You mentioned some of the background. It'd be great to sort of talk for a moment about re-stage heart failure and then how it brought you to this study. Dr. Stavros Drakos: Thank you, Jane. So again, thank you for the opportunity to talk about the findings and the implications of this study. I like the way you are asking us to look a little bit at what led to this study and as you mentioned, the re-stage is a multi-center study that was performed in six US sites which showed in a reproducible fashion now given that we had single center studies from all over the world suggesting that, advanced heart failure is not an irreversible process that has to lead to end stage, an irreversible disease and what a re-stage demonstrated was that there is a subset of patients which if you select them based on clinical characteristics that we derived from other studies that were performed previously, you can achieve reverse remodeling, essentially a bad heart looking much better by every clinical, functional, structural characteristic in up to 50% of the selected patients. That's what re-stage showed. So having this finding now in a multicenter study, what made this study very timely was to be able to understand what drives this remarkable response. What are some of the mechanisms, as Hesham said, that we can if uncover take advantage of and expand this paradigm and enhance it and achieve reverse remodeling and recovery of even more patients and even go earlier in the disease process. So that's kind of how I would link the clinical findings that preceded this study with the motivation to perform the study and the implications of these findings for the ongoing translational and basic science research. Hesham Sadek: I'd like to ask a question here. So Stavros, do you think it's too early to sort of redefine the term reverse remodeling in this context to include perhaps some evidence of regeneration? Is there evidence of regeneration in this field or that's too premature to say? Dr. Stavros Drakos: I think the data are directing us towards the direction you just mentioned. I think that we can begin talking about it and planting the seed. We do have other evidence from work that you and others have performed indicating that this indeed is one of the mechanisms that drives this phenomenon and I think that the findings, especially in the cell cycle that we identified add to and contribute even more to that body of work that you and others have done. At this point, I will turn it to Sarah who can talk a little bit more about the findings related to the cell cycle that we identified in our study and I think that these may complete the answer to you, Hesham. Dr. Sarah Franklin: Yeah, I would love to comment. I think it's a really interesting phenomenon and really in these patient samples we were trying to understand molecularly what the difference is between individuals that respond positively to therapy and individuals that receive the same exact therapy and do not respond positively. So these are termed responders and non-responders and in our analysis we combined two platforms where we could molecularly interrogate what's different in these two tissues and try to see what is differentiating these populations. So what's consistent and reproducible different in responders and non-responders on a molecular level and in both the transcriptomic data and the phospho proteomic data, we saw clear patterns with cell cycle regulation and extracellular matrix or focal adhesion molecules and the interesting thing about cell cycle is cardiomyocytes have typically been thought to exit the cell cycle not long after birth and we see some interesting phenomenon either in humans or mice where we can have nuclei that have either multiple sets of chromosomes or multiple nuclei and there's some differences that have been observed in the nucleus with regards to disease, so hypertrophy, heart failure. So the molecules that we've identified, we saw a large difference in proteins involved in cell cycle regulation. Now the interesting thing is not all of those molecules are increasing or decreasing. We see a combination of molecules that are increasing or decreasing. But I think the other thing that's interesting is that these molecules, even though we are seeing changes in expression or changes in phosphorylation, exactly how that contributes to either cell cycle or cell cycle reentry or just nuclear function and transcription of proteins or genes or DNA regions is still what we need to continue to study. So exactly how these changes in proteins or transcripts related to the cell cycle, how they are exactly contributing to the physiological improvements that we're seeing is something that still needs to be investigated but is really important that that is a highlight of this study and as Stavros mentioned of previous work. Dr. Maryjane Farr: Stavros, tell us the design of the study. Dr. Stavros Drakos: Okay. So this study was performed in 93 patients that were prospectively enrolled in the Utah transplant affiliated hospitals here in Salt Lake City between the University of Utah, Intermountain Medical Center and the VA and these people came from all over the mountain west, the surrounding states of Utah and through our VA, through the state, from all over the west and south, from Alaska and Hawaii to Texas and we think it's a very representative population of our country's patient population and then we followed prospectively these people with serial echocardiograms so we can tell who will respond as Sarah said before, which essentially means which hearts are going to get better by echocardiographic criteria functionally and structurally, the dimensions of the heart shrinking and the ejection fraction improving to more than 40% and the dimension shrinking to normal range and then we compare these people, the subset of patients that have responded to the majority of patients actually that they have not responded. As we know these are advanced end stage patients and there is only a subset of those that they will favor respondents. As we said earlier, these subset can increase if you go selectively and pick these patients based on baseline characteristics. So then we analyze the tissue we got from these people when the LVAD went in, which is the core of the apex of the heart and compare that to the tissue we receive when the patients got transplanted and we got the whole heart. So in the meantime, as we just discussed, we phenotyped these people so we knew who were responders and non-responders and then we went back in the lab and tried to marry two basic processes, analyzing the transcriptome and the proteome and by doing that we were able to see some overlapping changes between the transcriptome and the proteome and we felt that by doing this overlapping analysis, we will increase the likelihood that what we are seeing, exponential mechanistic drivers will be the real mechanism and not just associations that you can frequently find when you do studies in humans and that's kind of a rough, brief summary of the design. Sarah, would you add something to that? Dr. Sarah Franklin: No, I think that's a great overview of it. I think what excites me about it is that this was first clinically observed that these patients were recovering and so I think the exciting part is the hypothesis was that there was some molecular underpinnings that could molecularly define these patients that were responding or not responding and so with that hypothesis we then carried out these analyses hoping that we would see a difference and we're very excited. It's very successful in that we found very clear, molecular differences that are reproducible between these patient populations. Dr. Maryjane Farr: So obviously there's lots of implications. Let me start with one very simple clinical one and that is, so based on some of the differences in the signatures and pathways that you saw for the next patient who needs LVAD therapy and you're trying to predict in some way whether they may be a responder or a non-responder, could you look at a biopsy sample and try to make some sort of prediction based on some of your findings so that they can choose a VAD over a transplant? That's a very clinical question and then I guess the second question is would it have to be a left ventricular myocardial sample? So are the differences? What do you think about that question? Or it's just too much too, far beyond? This is obviously a mechanistic study. But I'm just asking. Dr. Stavros Drakos: No, that's a great question and I'll start and Sarah can add later. So obviously it will be great if we can have a practical way to predict before the intervention who are the people that they will respond and that's one of the motivations for this study. It was not just to find the mechanism so we can make this phenomenon better and enhance it and find the mechanism, create new therapies. It was also the practical approach that you suggested, Jane, and I think that yes, this adds to the clinical predictors that we have already identified from other studies and yes, we could theoretically take the tissue and do this analysis. Is this the most practical thing we can say to the patient to biopsy the heart, right? It would've been better to be able to identify a biomarker in the plaque and we've done that. We started in other studies, identifying what's going on in the tissue and then going targeted in the blood and that's how we identified two cytokines and a two cytokines model, interferon gamma and TNF alpha being predictive as circulating biome. In this study we identify changes that can also inform future studies of biomarkers in the blood. But if we had a way to easily get the tissue and analyze the genes, yes, we could have done that as a predictor as well. The practical issue is that asking a patient for a biopsy just to predict the response to therapy may be something that most patients and most clinicians will consider way too advanced and complicated, right?that's why more work should and could be done to identify circulating biomarkers or other modalities that can help us interrogate what's going on in the heart related with these findings. But not that we cannot also do what you said. It's just more complicated. I don't know if Sarah would like to add to this. Dr. Sarah Franklin: I'd love to. I think that's a great overview. I think the only thing that I would add is that there are a number of conditions whether in the heart or otherwise in the body that you can use a single biomarker and it can be very predictive of conditions. Heart failure is so complex that often individual biomarkers are not sufficient enough to cover an entire population and all the nuances that can go into heart failure symptoms or syndromes and I think the exciting part about this study is it is one of the largest cohorts of patients that have been examined in this manner, which is exciting, but also that we have a multi-factor panel that is made up of multiple biomarkers that with the number of individuals that we examined is completely predictive of all of these patients. So these biomarkers are consistent and reproducible across all of these patients between responders and non-responders regardless of some of the nuances in the heart failure that they have and so it's very exciting because it's possible that a multifactorial panel could be much more applicable and last the test of time more so than an individual biomarker. I think the one other thing that is exciting like Stavros mentioned is that we did initially identify these in the left ventricle and it will be really exciting to see how far these biomarkers can be used if they can be used in potentially other aspects of the heart or blood, which obviously is less invasive and so that's not something that we've applied this panel to yet, but I think is a really wonderful extension of now saying, can we also identify some of these biomarkers in the blood which would be less invasive even if it's a fraction of them. That would still be wonderful. Dr. Maryjane Farr: I have so many clinical questions. But Hesham, what questions do you have? Hesham Sadek: Yeah, so the elephant in the room here obviously is that the variable is that these patients have an unloaded heart and there is evidence that unloading can reverse some of the changes that occur after birth with increasing ventricular load and initiate cascade of molecular events that may allow myocytes to proliferate. So this begs the question, is there a difference in how these ventricles of patients that recover versus those that do not recover see load? Are we able to measure load appropriately and is there a difference in load between these patients and if so, can this be improved or detection or measuring unloading or the degree of unloading clinically, can this be improved? Dr. Stavros Drakos: No, that's a great question and it provides the opportunity to talk about some of the things we can do on the clinical arena to further enhance this phenomenon. Yes, there are ways that we can use to tailor the mechanical unloading that we can provide in order to enhance this phenomenon. One way, and that's a study that we are proposing, is to use sensors, pressure sensors that can guide the way you function the machines, the devices, right? The way you remove part of the load and these sensors, some of them are clinically approved like cardioments and then without doing invasive procedures you can follow chronically how these patients are being unloaded and how the heart is responding to this unloading. We know that a lot of LVAD patients, despite doing clinically well, we know this from snapshot evaluations in right-heart cath studies, they are not optimally unloaded. They are feeling pressures left and right are not always optimized and so by doing this kind of prospective assessment of the mechanical unloading, you can tailor what you offer and the hypothesis generated is that by doing that you may be able to recover even more people. You can do this as we said, with approved sensors like cardioments or with other sensors that they are under investigation. You can also do more invasive stuff like PV loops. Of course these will require cathing these patients, which is a little bit more complicated. But it will provide more accurate assessment and it will also interrogate how the heart is improving and provide to you in-depth investigation and in-depth insights on also how the recovery process and the reverse remodeling process is being, I would say, digested by the heart and translated to functional response instead of just looking at it with an echocardiogram or the findings of a right-heart cath and these are studies that others have performed and have published and we know that they can give you a real good look into the systolic and diastolic function of the heart and how this is changing and improving down the road. So yes, that's the short answer. We can do that and we can tailor the unloading and potentially that's the hypothesis, maximize the effect that we saw here. Hesham Sadek: So this begs the question, maybe two questions here. One, is there evidence that patients who recover not from this study only but from other studies, is there evidence that patients who recover are more unloaded than patients that do not recover and the second question is: is it time to standardize assessment of mechanical load in patients with LVAD, especially those that will undergo or would be considered for recovery? Dr. Stavros Drakos: Yes. So that's a great opportunity to share with our audience what we know and what we don't know in this field in relation to your question about whether we know what is the optimum degree of unloading and the answer I think is that we need to know and understand more. What do I mean by that? There's this idea that the heart as every other organ after being unloaded and not working for some time may it lazy, may get atrophic and may need some rehab like the skeletal muscle when we put it in the cast and get atrophic and we need to rehab it when we remove the cast. So you can imagine that the LVAD and the unloading that provides, which in many cases may take over a significant part of the function of the heart may need gradual reloading as a second phase after the first phase of unloading and that's something that we've done. We have an ongoing study on this and also others have published that it may be beneficial. Of course, it needs to be validated and investigated further and to discuss about the degree of unloading in the first phase and what is the optimum degree of unloading, I would say even there, there is room for us to understand better what's going on and I think that we can investigate with ongoing studies right now whether full unloading versus partial unloading and measure the pressures using these sensors can translate to better changes functionally and structurally. I think that's something that is very doable and it would be very beneficial. What was the second part of your question, Hesham? Hesham Sadek: I was asking whether it's time to start standardizing some measure of unloading if these patients are planned for recovery? Dr. Stavros Drakos: Yes, and that's what we are doing. In all of these people, we report from the get-go what is their recovery score based on the intermixed ICARS derived score and when we have patients that they have high likelihood of recovery, we monitor them very closely and clinically what we do is just looking at the echo and whenever we do a right heart cath for clinical reasons. But in a prospective research study we could do more than just looking at the echo and occasional right heart cath and using the sensors we just discussed previously, you can tailor the unloading and begin prospectively unloading them in a more I would say well monitored wave. Yes. Hesham Sadek: So this is unloading or device specific parameters. Now are there patient specific parameters with regards to type of heart failure? So we talked initially about whether there's an element of regeneration specifically when it comes to cell cycle. But many patients with non-ischemic cardiomyopathy for example, don't have large scars and don't have lot of myocytes as the underlying cause of cardiomyopathy. Would you foresee that there is different mechanisms, for example, in these patients that don't have myocyte loss, that perhaps maybe it's not cardio myocyte proliferation and not regeneration? Dr. Stavros Drakos: Yes. So I think that the differential responses we get based on the heart failure theology warrant further investigation. Sarah and I have discussed that and actually we are following on our findings with larger number of patients so we can tease out these and I'll let Sarah talk a little bit more about it in a minute. But to answer the clinical part of this question, we don't know yet whether different parts of heart failure should be prescribed different modes of unloading. But the way you described it of course invites the hypothesis that of course different substrates, different injuries of the heart, as you said, it's a completely different failing heart if you have a big scar there versus a patient who has a mode of heart failure, another type of injury and would this be treated better and more effectively in terms of reverse remodeling by applying a different mode of unloading? That's things that we need to investigate further. But Sarah, would you like to comment on the potential on the effect of the different heart failure theologies on some of the findings we saw? Dr. Sarah Franklin: Yeah, definitely. So I think it's a really interesting question and in this analysis we included ischemic and non-ischemic samples in the patient populations and really we're just stratifying them based on responders and non-responders. When we start layering additional levels onto that, then we're effectively kind of reducing the potential numbers. So if we have 25 responders and we start breaking that down into ischemic and non-ischemic to see if there's another layer of biomarkers there, we actually did that we did not include it in this study. It's something that we're working on to add that. But we do reduce the number overall of patients in those two populations. So it would be fine to share that we were seeing stratification between ischemic and non-ischemic. But we did not feel like the numbers might be high enough within the responder and non-responder categories that warrant including that in this manuscript. So it's very intriguing that just responders and non-responders alone stratify as well as they do. They separate based on these biomarkers and it looks like it will also be possible in the future for us to even separate these samples further based on similar or additional biomarkers based on more specific factors in the etiology. So I think that will be another really exciting next step for future research. Hesham Sadek: My final question would be maybe a little bit broader than LVAD population, but definitely informed by this study. The term non-ischemic cardiomyopathy, do you think it's too broad and too vague for us to use in this setting because this encompasses many different types of cardiomyopathy that really are not nuanced enough by this definition. Dr. Stavros Drakos: Well, Jane was smiling while you were asking this question because we all as heart failure clinicians need to accept that it was not a good idea to name all of these different diseases non-ischemic cardiomyopathy when we did it or when this happened many moons ago. As you said, Hesham, and I couldn't agree more, these are completely different diseases. We need to understand them better and I think that the way we treat nowadays, chronic heart failure, many years down the road when people will look back, they will consider it a little bit, I would say, surprising that we were treating all of these the same way. We need more studies like the one we just did, that they will have enough numbers and that's when the issue becomes that you need enough numbers to be able to tell the differences between all of these non-ischemic cardiomyopathy types, theologies and if you go upstream, motivated and inspired by findings like this, we hope that we will be able to identify how to go and do a root cause analysis and treat these diseases, not down, down, downstream the same way, but going upstream, finding what really went wrong and treating them earlier in the molecular or other pathophysiological mechanism pathway that led to the heart failure and so yes, it was a bad idea to do that. But of course sometimes we do things because we don't understand it better, right? As one of our keynote speakers here in the recovery symposium said a few years ago, Jay Khan, the founder of Heart Failure Strata of America, some things look complicated until you understand them. Then when you understand them, they look simple. So here we don't really understand non-ischemic cardiomyopathy and how all these theologies lead there and I think studies like these can help us really inform the field better. But we will need, as Sarah said, more numbers. Dr. Maryjane Farr: So that was a great conversation. I wanted to just raise one last thing and that is what's so interesting about this cohort relative to re-stage heart failure is these were older patients and for re-stage heart failure, I think the average age was 35. So you would imagine there might have been one etiology for cardiomyopathy, uncontrolled hypertension or peripartum. But for cohorts in their fifties, there's probably an accumulation of different insults over many years time and so I thought that was particularly interesting from the point of view of that you were probably dealing with, again, a mixed bag of pressure overload, volume overload, maybe a genetic underpinning, whatever the life trajectory of some of these patients were and then lastly, the decision to try to go to recovery rather than to transplant, which would be the real world experience of why this wet pathway than the other. These are people truly in their fifties where they may have one or two surgeries in their lifetime left and so it's the relevant population that you're studying and so I'll leave it at that. That's a comment rather than a question, I think. But I think for heart failure clinicians, this is why the bench to bedside piece is so relevant to understanding this because it actually does change clinical practice, even if the mechanistic pathways may take still many more years to truly understand. It helps understand what's possible from an accrued clinical decision-making level. Dr. Sarah Franklin: Jane, if I might just comment on that, I actually think that's one of the most exciting parts about this dataset is that, as you mentioned, these patients have complex diseases. They are older. But yet we are still able to see consistent and reproducible differences between the patient populations that respond and don't respond and to me that suggests that at the end of the day there are consistent differences or reproducible or consistent molecular changes in cardiac tissue and in response to stress and I think that that gives us hope that we could potentially not only predict who would respond or not respond, but that as we get better at understanding the differences, that there could be potential therapeutic targets or therapies that would still be beneficial regardless of the complexity of the heart failure. Dr. Maryjane Farr: Okay. So Sarah, Stavros, thank you so much for spending time with Hesham and myself and look forward to EUCORS--I'm allowed to say that. Dr. Stavros Drakos: Of course. Dr. Maryjane Farr: Thanks so much. Bye. Dr. Greg Hundley: This program is copyright of the American Heart Association 2023. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

هشام نزيه ملحن و موسيقي مصري وأحد أشهر وأهم مؤلفي الموسيقى التصويرية للأفلام والدراما التلفزيونية وحائز على العديد من الجوائز . ألف أول موسيقى تصويرية عام ١٩٩٨ لفيلم "هيستيريا"، ثم تلاه بعدد زاخر من الأعمال المهمة كفيلم "الساحر" و "إبراهيم الأبيض” التى شكلت موسيقاه فيه نقلة نوعية في مسيرته والموسيقى التصويرية المصرية و “تراب الماس “  و” الفيل الأزرق “ ، كما ألف موسيقى  مسلسلات "نيران صديقة" ، و"السبع وصايا” و” أفراح القبة “ . ازدادت شهرة هشام نزيه وأصبح من أكثر الشخصيات الفنية شهرة إثر تأليفه الموسيقى التي رافقت موكب نقل المومياوات الملكية إلى المتحف القومي في عام ٢٠٢١ إخترق نزيه مجال العالمية بأن تم ترشيحه لتأليف الموسيقى التصويرية لحلقات مارفل " مون نايت " لشركة ديزني العالمية والتي رشح عنها لجائزة الإيمي العالمية . كما ضمته لجنة جوائز الأوسكار ليكون عضوا دائما في لجان تحكيمها Produced by: Abbas Aboelhassan Follow: rwa.podcast.egInstagram: https://www.instagram.com/rwa.podcast...Facebook: https://web.facebook.com/rwa.podcast.egTwitter: https://twitter.com/rwa_podcast_egTiktok: https://www.tiktok.com/@rwa.podcast.egFollow Abbas Aboelhassan: Instagram: https://www.instagram.com/abbasaboelh...Facebook: https://web.facebook.com/AbbasyzFollow Hesham Nazih:Instagram:https://www.instagram.com/heshamnazih/Facebook: 

Studio Soundtracks takes listeners behind the scenes of how music is crafted for film and television by hearing directly from composers, songwriters and music professionals in the Entertainment Industry. Listen to inspiring conversations about composition and hear works from Emmy, Grammy, and Oscar-winning film scores on the show. Natalie Holt is a multi-award-winning British composer, known for her Emmy-nominated score for Marvel Studios' Loki and the acclaimed Lucasfilm series Obi-Wan Kenobi. Upcoming projects include DC's Batgirl. Her film and television credits include the BAFTA Award-winning series Wallander (BBC), Knightfall (History Channel), the BAFTA Award-winning series Three Girls (BBC), mini-series Deadwater Fell, the Emmy Award-nominated series The Honourable Woman (HBO Max), Victoria (PBS), Saul Dibb's World War I feature Journey's End, Netflix/Claudia Llosa's drama feature Fever Dream, and Fox's female super hero feature The Princess, to name just a few. Natalie's numerous awards nominations and wins include the Primetime Emmy Awards, World Soundtrack Awards' “Television Composer of the Year”, BAFTA, SCL Awards, the Royal Television Society Craft and Design Award, the HMMAs, and “Best International Score” at the Beijing International Film Festival. Hesham Nazih is an award-winning and Emmy-nominated Egyptian composer best known for his unique style that interweaves a mix of melodies from different cultures, creating an authentic genre all his own. He has scored over 40 award-winning films that have dominated the Egyptian box-office such as director Marwan Hamed's musically-intense horror features Blue Elephant and Blue Elephant: Dark Whispers, as well as director Tarek Alarian's Sons of Rizk 1-2, his breakthrough score for Snakes and Ladders, as well as Marwan Hamed's Ibrahim Labyad. Nazih marked his first major English language project with his Emmy-nominated score for Marvel Studios' Moon Knight on Disney+, for which he was also invited to become a member of The Television Academy. He has also composed for critically acclaimed Egyptian television works including The Seven Commandments and Shahid's first original Egyptian series Every Week Has a Friday, which earned Egypt its first-ever International Emmy nomination. Among Nazih's other most notable works, he earned both international attention and acclaim for his original music and songs written for the lavish live production The Pharaohs' Golden Parade in 2021, and he is the first and only composer to ever receive the honorary Faten Hamama Excellence Award from the 2018 Cairo International Film Festival.

Biden set to meet nine Middle East leaders, USIP’s Ambassador Hesham Youssef says the trip aims to untangle recent tensions rather than “result in all kinds of breakthroughs and deliverables … the question is whether we can set ourselves on a path that can lead to more constructive relations.”

In this episode of Frankly Speaking, the Deputy Minister Of Hajj & Umrah Services and Official Spokesperson talks about what it takes to prepare the first Hajj pilgrimage in more than two years and the measures the Ministry is taking to keep people safe during this sacred event.

Helai Hesham is a board-certified doctor of Obstetrics and Gynecology, subspecializing in female pelvic medicine and reconstructive surgery. She is an assistant professor of Female Pelvic Medicine and Reconstructive Surgery at Columbia University Vagelos College of Physicians and Surgeons and completed her fellowship at Harvard Medical School Massachusetts General Hospital. Dr. Hesham sits down with Women on Top with Haleh Moddasser to discuss her experience as a young Afghan refugee, the impact of being raised by a strong female doctor, what Covid revealed about healthcare in the U.S., plus her passion for helping women in poverty.

0:00 SEG 1 Michael Rosenbaum (https://twitter.com/michaelrosenbum) talks about attending FanExpo St. Louis, Superman Celebration in Metropolis, booking guests for his podcast ‘Inside of You with Michael Rosenbaum', losing his grandfather, Steven Amell having an anxiety attack on the podcast, being grateful for his Patrons, what's in store for Superman Celebration, Lex Luther and The Flash crossovers, plans for a Superman animated series with Kristin Kreuk and Tom Welling, appreciating Smallville, meeting Bruce Timm, his favorite item from his collection, stealing Lex Luthor's belongings from the set, and what recent horror films have impressed him. 24:56 SEG 2 Composer Hesham Nazih (https://twitter.com/heshamnazih) talks about making the music for ‘Moon Knigh't on Disney+ 41:32 SEG 3 Part 2 with composer Hesham Nazih Thanks to our sponsors Marcus Theatres (https://www.marcustheatres.com/), Historic St. Charles, Missouri (https://www.discoverstcharles.com/), Bug's Comics and Games (https://bugscomicsandgames.com/), and Kokomo Toys and Collectibles (https://www.kokomotoys.com/) Amazon Affiliate Link - http://bit.ly/geektome Buy Me a Coffee - https://www.buymeacoffee.com/3Y0D2iaZl Patreon - https://www.patreon.com/GeekToMeRadio Website - http://geektomeradio.com/ Podcast - https://anchor.fm/jamesenstall Facebook - https://www.facebook.com/GeekToMeRadio/ Twitter - https://twitter.com/geektomeradio Instagram - https://www.instagram.com/geektomeradio/ Producer - Joseph Vosevich https://twitter.com/Joey_Vee --- Support this podcast: https://anchor.fm/jamesenstall/support

Hesham Nazih is a composer based in Cairo, and the first Egyptian composer to score a Marvel project with MOON KNIGHT. In this interview, Hesham details how he got the job, the spectacular vocal effects in the music, and the difference between the Hollywood sound of Egypt and the real thing — and how they've grown together. Plus, Hesham's story of being unable to afford musical training, and his process of self-teaching from playing in bands to meeting young filmmakers who needed scores. And the lesson one filmmaker shared with him about being unafraid to say “no” when you don't believe in the project. Interview by Matt Schrader.

One of the most heartening things about Disney+'s run of Marvel TV shows is that they seem to be an interesting staging ground for new ideas, the exploration of new communities, and -- most importantly for our interests -- new artists to reach broader audiences. That's certainly the case with Marvel's latest series in the MCU, Moon Knight, which sees Oscar Isaac as Marc Spector/Steven Grant, a pair of dissociative identities sharing the same body, which also happens to be able to summon the spirit of the Egyptian god Khonsu and turn them into the avenging superhero Moon Knight.   The series itself is a brisk, fun Indiana Jones-type adventure, wafting between breezy action sequences and more sobering explorations of the trauma of mental illness, child abuse, and more. But given its Egyptian setting, it's heartening that the vast majority of the talent both in front of and behind the camera are Egyptian, from its director Mohamed Diab to composer Hesham Nazih, a veteran film and TV composer with reams of accolades and more than twenty years of experience in Egyptian media.   For Moon Knight (his first English-language score), Nazih crafts a score that is both indebted to the gee-whiz adventure influences of the show itself and the cultural markers and musical identity of Egypt itself, combining the two into a unique musical synthesis that echoes the balancing scales Marc and Steven have to achieve in order to make themselves whole. Egyptian instruments combing with Arabic-language choir and the bombastic, brass-heavy sweep we expect of superhero blockbusters to create something that feels wholly new, while avoiding the cliches of most Western scores set in the Middle East and North Africa.   For the podcast, Hesham was lovely enough to sit down with me (on the first day of Eid al-Fitr!) to talk about transitioning his robust skill set to Marvel, weaving his own influences within the score while avoiding stereotype, and how his score fits in with the show's use of mahgraganat (a budding genre of exciting, fist-pumping protest music making waves in Cairo the last few years) in the musical fabric of the show.   The entire first (and only?) season of Moon Knight is currently streaming on Disney+. You can also listen to the score for Moon Knight on your preferred music streaming service courtesy of Marvel Music.

3:00 - Jon Watts leaves Fantastic Four 8:00 - Voice Message 1 Doctor Strange 14:48 - Voice Message 2 Wanda Maximoff 25:10 - Gregory Middleton Interview (Cinematographer) 34:30 - Moon Knight Episode 5 Leftovers 1:05:23 - Hesham Nazih (Composer) Interview Learn more about your ad choices. Visit megaphone.fm/adchoices

Children Around The Prophet PBUH (1 Intro) Dr Hesham al Awadi

Hosts Gil Bashe and Gregg Masters welcome two compassionate physicians 'advocating for change.' OB/GYN Jeff Livingston MD and CEO of Macarthur Medical Center and Rush University critical care hospitalist Hesham Hassaballa MD weigh in on the general theme of clinician vulnerability and who heals the healer? Clinician burnout including growing professional exits, staffing shortages and disturbing levels of suicide and depression have reached unprecedented levels as the pandemic continues to take a toll on our frontline clinicians, challenging their emotional, physical and spiritual reserves. Advocating for change, both suggest vulnerability and clinician support systems are critical to the health and wellbeing of clinicians. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Hesham Baalawi is OZ Media's/The Yemeni American News' April Rising Star High School Student-Athlete of the Month.Get to know Hesham. Here is a quick player profile:Name: Hesham BaalawiSchool: Edsel Ford High SchoolSport/Position: Basketball/Point GuardGPA: 4.166The Yemeni American News Article:This episode was sponsored by Unique Coney Island, Fordson Quick Lube and Hammertime True Value Hardware.#Student #athlete #of #the #month #hard #work #dedication #commitment #dearborn #highscool #thunderbirds #dps #ozmedia #yemeniamericannews #youtube #apple #spotify #podcast

Pr. Hesham Shehab of Peace Lutheran-Lombard, IL and Salam Christian Fellowship  

I❤️ARR Podcast with Aditya Modi In this episode, I had the honour of having the amazing Hesham Abdul Wahab. We spoke about his journey, his love and admiration for ARR Sir. This Podcast is all about pure love for ARR Sir. A little note from me - Hesham is one of us. He has worked very hard to get to where he is today. And above all he owes it all to ARR Sir. I highly recommend this Podcast :) I have passionately worked on the post production of this Podcast. It has taken me hours of hard work for this episode. Hope you enjoy :).

First in an series based on the book by Dr. Hesham al-Awadi. Presented by Shaykh Jamaal Diwan.

With Poseidon, Livinia, Hesham, Hasnaa, Jack Bosma and Black from Free4Talk. --- Send in a voice message: https://anchor.fm/jack-bosma3/message Support this podcast: https://anchor.fm/jack-bosma3/support

دي حلقة استثنائية (لسة قيد الإعداد) بحاول استوعب الصدمة اعذروني...خارج محتوى القناة تماماً الحلقة دي اهداء لروح الصديق العزيز والاخ دكتور هشام عبداللطيف...اللي فارقنا فجأة وكان له افضال كبيرة علي...جايز دة Exposure شخصي ليا بس دة حاجة من اللي اتمنى أذكره بيها والناس تعرفه بيها...فيه ناس فقدها بيشعرك باليتم لمجرد أنهم كانوا سند حقيقي...هشام كان كدة بالنسبة لي ولأي حد عرفه...ادعوا له بالرحمة والمغفرة واتمنى ارثه اللي سابه فيا اقدر اكون سبب في أنه عمله وعلمه يمتد في الدنيا بعدها...الله يرحمك يا هشام --- Send in a voice message: https://podcasters.spotify.com/pod/show/lazy-hypster/message

An international educational podcast for professionals and patients all about the finer details of rhinoplasty. In each episode, we travel the globe talking to world-leading plastic surgeons, hearing their unique stories, and learning from their experiences.

An international educational podcast for professionals and patients all about the finer details of rhinoplasty. In each episode, we travel the globe talking to world-leading plastic surgeons, hearing their unique stories, and learning from their experiences.

       In this podcast, the entire crew from the GoToDentist Podcast welcomes Dr. Hesham Sherghin onto our virtual set. At just 34 years old, this young dentist has created a phenomenal multilocation dental practice, two other businesses that support practicing dentists, all the while working on his MBA.        You will hear the passion in Hesham's voice, the clarity of his vision, and the business principles he utilizes to manage his time, inspire his team, and make a difference in the lives of his team members as well as his customers.          We were captivated by this young man. Our biggest takeaway was that it really does not matter if you are a small dental practice with 3 team members, or creating a multilocation machine. To have success your vision has to be clear and understandable. The leader has to passionately lead, and when obstacles come (and they will), you must have the persistence to overcome. David, Pio, and John learned a ton from this young professional, we hope you do as well!

Tonight we talk with Alex Winter Director of Deep Web co-hosted by Julia Tourianski. Then we discuss the Paris Attack with Hesham El-Meligy from Muslims4Liberty. We get into misconceptions, Buzz words and general Islamaphobia.

Hesham Abdul Wahab joins us this episode to give insight of his musical career beginnings. He is a young, talented singer/songwriter of Indian decent but grew up in the Middle East. He performs in multiples languages such as Hindi, Urdu, Malayalam and English. Since his introduction to Sami Yusuf's Andante Records in 2011, he has... The post EP 41 – Hesham Abdul Wahab of Andante Records appeared first on Greed for Ilm.